Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
31 August 2022 | Story Prof Motlalepula Matsabisa | Photo Andrè Damons
Prof Motlalepula Matsabisa
Prof Motlalepula Matsabisa, Professor and Director of Pharmacology, Faculty of Health Sciences, University of the Free State. He is also leading Africa’s fight against the COVID-19 pandemic after being appointed as chairperson of the World Health Organisation’s (WHO’s) Regional Expert Advisory Committee on Traditional Medicines for COVID-19.

Opinion article by Prof Motlalepula Matsabisa, Professor and Director of Pharmacology, Faculty of Health Sciences, University of the Free State.
As we celebrate African Traditional Medicine Day on 31 August to promote the important role of the continent’s rich biodiversity in improving well-being, one needs to acknowledge the role that COVID-19 played in shining a spotlight on African traditional medicines (ATMs). Responding to the pandemic, rapid vaccine research and development and the repurposing of drugs in the fight against COVID-19 happened on great scales. Traditional medicines also benefited from renewed interest as a possible solution for this deadly disease. This year the World Health Organisation (WHO) Regional Director has approved the theme for the celebration of the 20th anniversary of African Traditional Medicine Day as ‘Two Decades of African Traditional Medicine Day: Towards Achieving Universal Health Coverage’. Countries will be celebrating individually, while WHO will hold a virtual celebration on the day. 

Even though ATMs, similarly to other traditional medicines such as those from China and India, have been used by African people long before the advent of “modern” medicine, and still continue to be used for the treatment of a range of diseases, most people still do not believe in its value as medicines for serious and chronic illnesses. This might be because of the lack of scientific research behind these remedies, and the dominance of the Western knowledge system and its wide acceptance by younger generations who value more Western values and lifestyles while being oblivious to ATMs. But in Africa, where about 80% of the population are said to rely on traditional medicine for their basic healthcare needs (according to the WHO), ATMs should be given a more prominent role. They should be more visible on shelves in big pharmacies, prescribed by healthcare practitioners beyond just traditional health practitioners (THPs), and should be more mainstreamed than what is currently the case. 

UFS Department of Pharmacology made great strides researching ATMs

Over the past few years, the University of the Free State (UFS), through its Department of Pharmacology, has made great strides in researching the possibilities and potential of ATMs. My team and I, together with other role-players in the institution, are in the process of establishing one of the most advanced modern pharmacology GLP-accredited research and development laboratories in the country, and possibly in the region, after receiving a grant of R58 million from the government. The UFS is recognised as a national leader in pharmacology as well as research and development of indigenous knowledge systems (IKS) and traditional medicines. The UFS has developed and built infrastructure in this field of scientific research, and has the best modern equipment for the training, teaching, and development of prototypes and products for commercialisation based on IKS. Interdisciplinary and interfaculty research is undertaken in this study area, and we have an excellent track record of sound community engagement with relevant stakeholders. 

The department has also been awarded an annual Technology and Innovation Agency Platform (TIA) grant of R17 million for the next five years. This research and teaching programme, known as African Medicines Innovations and Technologies Development (AMITD), will help to recruit and employ the best skills throughout the research, development, and herbal-medicine manufacturing value chains. We received a DSI high-end infrastructure (HEI) grant to build a laboratory, which will be a centre of excellence for the government, the WHO, and the African Union’s Commission for Social Development. The grant will also be used to build a herbal medicines production facility, as well as to pilot a health facility for traditional medicines. I am pleased that a multinational private pharmaceutical company has come forward and will be collaborating with us to realise these plans – joint manufacturing and business development, and joint engagement in the integrated health facility. We are now, together with the WHO and the aforementioned company, entering into a collaboration agreement to work together on key projects in traditional medicine manufacturing and training. 

Traditional medicine therapies emerged as possible cures or remedies for COVID-19

As part of the COVID-19 response, traditional medicine therapies have emerged as possible cures or remedies for the deadly disease. The pandemic has certainly helped to improve the profile of ATMs. In Cameroon, for example, two complementary therapy products for COVID-19 have been approved by the government, while Madagascar’s herbal remedy, COVID-Organics Plus Curative, has been in phase II clinical trials.  Encouraging preliminary results have been reported around this clinical trial. Similar trials on traditional medicine products for COVID-19 – conducted according to WHO protocols – are also underway in other African countries, including Democratic Republic of Congo, Nigeria, Uganda and South Africa, according to the World Health Organisation (WHO).

With regard to South Africa, my team and I and FARMOVS received approval from the South African Health Products Regulatory Authority (SAHPRA) to conduct the first multicentre controlled phase II clinical trial of a plant-based product, PHELA, on mild- to moderate-symptom COVID-19 patients.

The main purpose of the clinical trial is to confirm that the product can treat COVID-19 and be registered by the South African Health Products Regulatory Authority. We confirmed in vitro and in vivo that the medication works as an immune modulator to modulate the cytokine storm due to COVID-19, and also restores and normalises the patient’s immune system. This pivotal study is based on the modification of the WHO master protocol for clinical trials. The study is ongoing at three sites, and we are considering the addition of two more sites, to make a total of five clinical-trial sites. The development of PHELA has taken place under stringent scientific scrutiny in both preclinical and clinical research. The efficacy of PHELA as both an immune modulator and an anti-SARS-COV-2 treatment has been proven in in vitro and in vivo studies with reproducible results, conducted by three independent research institutions and a science council. PHELA is a herbal product made of four medicinal plants. Traditionally PHELA has been claimed for use for a historical disease called muyaga, but recently it has been scientifically tested and found effective as an immune modulator that benefits persons with a compromised immune system.

African Traditional Medicines Day: a reminder of the value and contribution of traditional medicines

The celebration of African Traditional Medicines Day annually on 31 August reminds all of us of the value and contribution of traditional medicines. This year’s theme on the role of ATMs in universal health coverage (UHC) is most befitting, as we know that medicines from natural products are affordable, accessible, have almost no side effects, and are proven enough because they have been advised for many generations, and they have been quite efficient in treating 90% of all currently known human diseases. The annual celebration, therefore, aims to gain more support for the continent to fast-track the research and development, as well as the local manufacturing, of well-researched ATM products, and for them to be made available through our national health systems. This also encourages the training of younger generations in this field of science and research.

Support for local manufacturing of ATMs will help bring traditional medicinal products into mainstream health systems and formal economies, creating jobs and wealth throughout all the ATM-manufacturing value chains – commercial cultivations, research and development, manufacturing, distribution, logistics, and marketing. This will help move the continent from dependency on aid from rich Western countries. Aid has not given Africans any independence, and has never been sustainable. It is, instead, enslaving the continent. If we want to be independent of big Western pharmaceutical companies and their expensive medicines, inequities and discrimination – as seen during the COVID-19 pandemic, African countries were left wanting when it came to access to personal protective equipment, diagnostics, therapeutics, and vaccines – Africa does not need aid. We need technical skills, technology development, and skill transfer. Aid makes African dependent, not independent. We need investment –  financial, research and resources – into developing our own, locally and regionally sourced herbal-based medicine. Africa and her people need African solutions to its health problems –and who could be better suited to create them than the continent’s people through its indigenous knowledge systems. 

Africa should be a leading force 

In August health ministers from Africa met at a special event – the WHO Health Ministers Regional Committee for Africa, in Lomé, Togo. The theme of the meeting was ‘Building Back Better: Rethinking and rebuilding resilient health systems in Africa to achieve UHC and health security’. The WHO Africa Regional Office hoped to develop a collective roadmap for building resilient health systems through integrated efforts that coordinated actions across all clusters and teams in the WHO’s regional office and country offices, and with national, regional and global partners supporting African countries as they ramp up efforts to recover from the pandemic-induced disruption and build back better toward achieving UHC and being prepared for future health emergencies.

As Chairperson of the Regional Advisory Committee on Traditional Medicine for COVID-19 Response (REACT), I gave a presentation on fast-tracking research and development and local production of herbal medicines during the second session, with the theme ‘Lessons to guide strengthening of health product manufacturing in Africa’. I am of the view that COVID-19 helped to prepare the continent for the next major event, and Africa will be better suited to deal with it. We cannot, again, be caught off guard and found wanting, and be at the mercy of the West for donations. I presented ways to put in place systems for supporting local manufacturing of therapeutics, with participation through the African regional economic blocks. 

News Archive

Studies to reveal correlation between terrain, energy use, and giraffe locomotion
2016-11-18



More than half of giraffes in captivity in Europe are afflicted by lameness. This high prevalence represents an important welfare issue, similar to other large zoo animals.

According to Dr Chris Basu, a veterinarian at the Royal Veterinary College in the UK, giraffes in captivity are often afflicted by overgrown hooves, laminitis and joint problems. Diagnosis and treatment is limited by our understanding of anatomy and function, more specifically the locomotion of these animals. Although the giraffe is such a well-known and iconic animal, relatively little has been studied about their locomotor behaviour.

Dr Basu recently visited South Africa to do fieldwork on the locomotion of giraffes as part of his PhD studies under the mentorship of world-renowned Professor of Evolutionary Biomechanics, Prof John Hutchinson. This project is a joint venture between Dr Basu and Dr Francois Deacon, researcher in the Department of Animal, Wildlife, and Grassland Sciences at the UFS. Dr Deacon is a specialist in giraffe habitat-related research. 

Together Prof Hutchinson and Drs Deacon and Basu form a research group, working on studies about giraffe locomotion.

Wild giraffe population decrease by 40% in past decade

“Locomotion is one of the most common animal behaviours and comes with a significant daily energetic cost. Studying locomotion of wild animals aids us in making estimates of this energetic cost. Such estimates are useful in understanding how giraffes fit into ecosystems. Future conservation efforts will be influenced by knowledge of the energy demands in giraffes.

“Understanding aspects of giraffe locomotion also helps us to understand the relationships between anatomy, function and evolution. This is relevant to our basic understanding of the natural world, as well as to conservation and veterinary issues,” said Dr Deacon.

Locomotion study brings strategy for specialist foot care

On face value it seems as if foot disease pathologies are more common in zoo giraffes than in wild giraffes. “However, we need a good sample of data from both populations to prove this assumption,” said Dr Basu. 

This phenomenon is not well understood at the moment, but it’s thought that diet, substrate (e.g. concrete, straw, sand and grass) and genetics play a part in foot disease in giraffes. “Understanding how the feet are mechanically loaded during common activities (standing, walking, running) gives our research group ideas of where the highest strains occur, and later how these can be reduced through corrective foot trimming,” said Dr Basu.

Through the studies on giraffe locomotion, the research group plans to devise strategies for corrective foot trimming. At the moment, foot trimming is done with the best evidence available, which is extrapolation from closely related animals such as cattle. “But we know that giraffes’ specialist anatomy will likely demand specialist foot care,” Dr Basu said.

Studying giraffes in smaller versus larger spaces

The research group has begun to study the biomechanics of giraffe walking by looking at the kinematics (the movement) and the kinetics (the forces involved in movement) during walking strides. For this he studied adult giraffes at three zoological parks in the UK. 

However, due to the close proximity of fencing and buildings, it is not practical to study fast speeds in a zoo setting. 

A setting such as the Willem Pretorius Nature Reserve, near Ventersburg in the Free State, Kwaggafontein Nature Reserve, near Colesberg in the Karoo, and the Woodland Hills Wildlife Estate in Bloemfontein are all ideal for studying crucial aspects such as “faster than walking” speeds and gaits to measure key parameters (such as stride length, step frequency and stride duration). These studies are important to understand how giraffe form and function are adapted to their full range of locomotor behaviours. It also helps to comprehend the limits on athletic capacity in giraffes and how these compare to other animals. 

Drones open up unique opportunities for studying giraffes

The increasing availability of unmanned aerial vehicles (UAVs)/drones opens up unique opportunities for studying locomotion in animals like giraffes. Cameras mounted onto remotely controlled UAVs are a straightforward way to obtain high-quality video footage of giraffes while they run at different speeds.

“Using two UAVs, we have collected high definition slow motion video footage of galloping giraffes from three locations in the Free State. We have also collected detailed information about the terrain that the giraffes walked and ran across. From this we have created 3D maps of the ground. These maps will be used to examine the preferred terrain types for giraffes, and to see how different terrains affect their locomotion and energy use,” said Dr Deacon.

“The raw data (videos) will be digitised to obtain the stride parameters and limb angles of the animals. Later this will be combined with anatomical data and an estimation of limb forces to estimate the power output of the limbs and how that changes between different terrains,” said Dr Basu.


Related articles:

23 August 2016: Research on locomotion of giraffes valuable for conservation of this species
9 March 2016:Giraffe research broadcast on National Geographic channel
18 Sept 2015 Researchers reach out across continents in giraffe research
29 May 2015: Researchers international leaders in satellite tracking in the wildlife environment

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept